GLP-1 Injection Protocol for Med Spas: Semaglutide & Tirzepatide Dosing Guide (2026)

What Is a GLP-1 Injection Protocol?

A GLP-1 injection protocol is the written clinical standard that governs how your med spa administers glucagon-like peptide-1 (GLP-1) receptor agonists — including semaglutide (brand names: Ozempic, Wegovy) and tirzepatide (brand names: Mounjaro, Zepbound) — to patients for weight management.

The protocol defines every step from patient screening through dose administration through follow-up monitoring. It's not just good clinical practice — it's a regulatory requirement in most states for any outpatient setting administering prescription medications.

A complete GLP-1 SOP covers four areas:

1. Patient eligibility and pre-treatment screening — who qualifies, what to assess before starting
2. Dosing schedules — specific milligram doses, escalation timelines, and criteria to pause or discontinue
3. Administration technique — how to prepare and inject correctly
4. Ongoing monitoring and adverse event management — what to check at each visit and how to respond when something goes wrong

This guide covers all four. If you need a ready-to-implement version with all required documentation fields, customizable for your practice, the Weight Loss Protocol Kit includes complete, medical-director-ready SOPs for semaglutide, tirzepatide, NAD+ IV, and IV vitamin therapy.

Patient Eligibility: Who Qualifies for GLP-1 Therapy

Before any dosing or injection discussion, your protocol must establish who is an appropriate candidate. GLP-1 medications are FDA-approved for weight management in adults who meet specific clinical criteria.

FDA-Approved Indications (Weight Management)

• BMI ≥ 30 kg/m² (obesity), OR
• BMI ≥ 27 kg/m² with at least one weight-related comorbidity: type 2 diabetes, hypertension, dyslipidemia (high cholesterol/triglycerides), obstructive sleep apnea, or cardiovascular disease

Patients who do not meet these criteria can still be prescribed GLP-1 medications off-label by a licensed provider who documents the medical rationale — but the prescribing decision must be made by the physician, NP, or PA, not by your med spa staff.

Absolute Contraindications — Do Not Proceed

Your screening must rule out the following before any GLP-1 therapy begins:

• Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 drugs carry an FDA black box warning for MTC risk based on animal studies
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2) — genetic condition that increases MTC risk
• Prior serious hypersensitivity reaction to semaglutide, tirzepatide, or any component of the formulation
• Pregnancy — GLP-1 drugs must be discontinued at least 2 months before a planned pregnancy (semaglutide) or 1 month (tirzepatide)

Relative Contraindications — Requires Prescriber Evaluation

• History of pancreatitis (acute or chronic)
• Severe gastroparesis or diabetic gastroenteropathy
• Severe kidney disease (eGFR < 15 mL/min/1.73m²)
• Active gallbladder disease (GLP-1 drugs increase gallstone risk)
• Current use of insulin or sulfonylureas (increases hypoglycemia risk — may require dose adjustment)
• Severe depression or suicidal ideation (monitor; FDA has issued safety communication on psychiatric risk)

Semaglutide Dosing Schedule (Wegovy / Weight Loss)

Semaglutide for weight management follows a structured dose escalation protocol designed to minimize GI side effects while achieving therapeutic effect. The schedule below reflects the FDA-approved Wegovy dosing protocol.

Tirzepatide Dosing Schedule (Zepbound / Weight Loss)

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it works on two pathways, which is why it typically shows stronger weight loss results than semaglutide alone. The escalation is slower due to a longer list of dose steps. The schedule below reflects the FDA-approved Zepbound dosing protocol.

Injection Technique: Step-by-Step Protocol

Correct injection technique minimizes adverse reactions, ensures full dose delivery, and reduces lipohypertrophy (fatty lumps at the injection site caused by repeated injections in the same spot).

Approved Injection Sites

GLP-1 injections are subcutaneous — into the fatty tissue just beneath the skin. Three sites are approved:

• Abdomen — at least 2 inches away from the navel in any direction; avoid the area immediately around the navel and any scar tissue
• Upper thigh — front or outer surface, middle third of the thigh; avoid the inner thigh and area near the knee
• Upper arm — outer surface of the upper arm; this site is typically used for self-injection and requires some patient coaching

Site rotation is not optional. Patients (and staff) must rotate injection sites each week to prevent lipohypertrophy. Document the site used at every visit. A simple rotation schedule: abdomen (left) → abdomen (right) → right thigh → left thigh → repeat, or as the prescriber's protocol specifies.

Step-by-Step Injection Procedure

1. Verify patient identity and prescription — confirm the patient, the correct drug, the correct dose, and the valid prescription before touching the medication
2. Remove the pen from refrigeration 15–30 minutes before injection — room-temperature medication is less painful and ensures proper viscosity for full delivery
3. Inspect the medication — should be clear, colorless to slightly yellow. Do not use if cloudy, discolored, or containing visible particles. Check expiration date.
4. Wash hands thoroughly with soap and water for at least 20 seconds
5. Prepare the injection site — clean with a fresh alcohol swab in a circular motion; allow to air dry completely (at least 15 seconds). Do not blow on or fan the site.
6. Prepare the pen — attach a new needle (if applicable to the device), prime as directed by the manufacturer, dial to the correct dose
7. Position the needle — for most patients, insert at a 90-degree angle. For very lean patients, use a 45-degree angle to avoid intramuscular injection. A skin pinch technique may be used in thin patients.
8. Insert and inject — smooth, continuous motion. Once the needle is in, press the injection button fully and hold for a slow 6-count (approximately 6 seconds) to ensure complete dose delivery. Do not rush this step — incomplete delivery is a common error.
9. Remove the needle — withdraw at the same angle it was inserted. Do not rub the injection site; gently hold a clean gauze pad to the site if needed.
10. Dispose of the needle immediately in a puncture-resistant sharps container. Never recap used needles.
11. Document — record lot number, expiration date, dose, injection site, time, and administering provider in the patient chart immediately after administration

Post-Injection Observation

• First-dose patients: observe for a minimum of 15 minutes for signs of injection site reaction or systemic hypersensitivity (urticaria, rash, dyspnea, angioedema)
• Established patients: minimum 5-minute observation; assess for any new symptoms since last injection
• Any patient reporting dizziness, shortness of breath, or rash post-injection: keep in clinic, notify the supervising provider, and follow your anaphylaxis protocol

Medication Storage Requirements

Improper storage degrades GLP-1 medications and can result in reduced efficacy or patient harm. Your SOP must address storage explicitly:

• Refrigerated storage: 36°F–46°F (2°C–8°C). Do not freeze. Store in original carton to protect from light.
• Room temperature: once removed from refrigeration, Wegovy may be stored at room temperature (up to 77°F / 25°C) for up to 28 days. Zepbound may be stored at room temperature for up to 21 days. Discard if not used within these windows.
• In-use pens: once a pen has been used, store without the needle attached, capped. Never store with needle attached — this creates air bubbles and risk of contamination.
• Temperature excursions: if a pen has been exposed to temperatures outside the range (e.g., left in a car in summer heat), discard it. Do not administer medication of unknown temperature history.

Monitoring Protocol: What to Assess at Every Visit

GLP-1 therapy is not a set-it-and-forget-it service. Your protocol must specify what gets assessed at each patient visit and what thresholds prompt escalation or referral.

At Every Injection Visit

• Weight and BMI — track trend; document if weight loss has stalled for 3+ consecutive months (may warrant prescriber review of dose or continued therapy)
• Blood pressure — GLP-1 drugs can lower blood pressure; patients on antihypertensives may need medication adjustment. Flag if SBP < 100 mmHg or significant drop from baseline.
• Symptom review — ask specifically about: nausea, vomiting, diarrhea, constipation, abdominal pain, injection site reactions, dizziness, and any new medications started since last visit
• Heart rate — GLP-1 drugs typically increase resting HR by 1–4 BPM; flag persistent tachycardia (> 100 BPM at rest) for prescriber review
• Hypoglycemia symptoms — required for patients also on insulin or sulfonylureas; ask about episodes of shakiness, diaphoresis, confusion since last injection

Recommended Monitoring Schedule

• Months 1–3: monthly in-clinic visits (or more frequently during dose escalation)
• Months 3–12: every 6–8 weeks, or at each injection if clinic-administered
• Maintenance (12+ months): quarterly, with prescriber reassessment at 6-month intervals
• Labs: the prescribing provider should order baseline labs (HbA1c, lipid panel, CMP, TSH) and follow-up at 3–6 month intervals; this is a prescriber responsibility but your protocol should confirm it's occurring

Criteria to Pause or Discontinue

Your protocol must define when to hold an injection and notify the prescriber:

• Patient reports severe, persistent abdominal pain — possible pancreatitis; hold injection, notify prescriber, advise patient to seek emergency care if pain is severe
• Patient is pregnant or suspects pregnancy
• Significant hypoglycemic episode since last visit in a patient also on insulin/sulfonylurea
• Active severe nausea/vomiting at time of visit — hold injection, ensure patient can tolerate hydration, notify prescriber
• Resting HR persistently > 100 BPM — notify prescriber before administering
• Patient has been hospitalized for any reason since last visit — notify prescriber before proceeding

Adverse Event Response Protocols

Your GLP-1 protocol must include specific response steps for the adverse events most likely to occur in your patient population. The following are the highest-priority scenarios:

Hypoglycemia (Low Blood Sugar)

Most common in patients who are also taking insulin or a sulfonylurea. GLP-1 drugs alone rarely cause hypoglycemia.

Recognize it: shakiness, diaphoresis (sweating), pallor, confusion, rapid heartbeat, hunger, blurred vision. In severe cases: loss of consciousness.

Respond:

1. Seat the patient immediately; do not leave them alone
2. If conscious and able to swallow: administer 15–20g fast-acting glucose (4 oz juice, regular soda, or glucose tablets)
3. Recheck in 15 minutes; if symptoms persist, repeat glucose administration
4. If unconscious or unable to swallow: call 911. Do not attempt oral glucose in unconscious patients.
5. Document the episode, blood glucose reading if available, intervention, and outcome
6. Notify the prescribing provider of any hypoglycemic episode — medication adjustment is typically needed

Pancreatitis Warning Signs

Recognize it: severe abdominal pain, often radiating to the back; pain that is persistent (hours), not just cramp-like; may be accompanied by nausea and vomiting; pain may be worse after eating.

Respond:

1. Do not administer the scheduled injection
2. If symptoms are severe: call 911 or direct patient to emergency room immediately
3. If symptoms are moderate and patient is ambulatory: instruct patient to go to urgent care or ER; do not let them drive themselves
4. Notify the prescribing provider and document all details
5. GLP-1 therapy should be suspended pending prescriber evaluation and resolution of pancreatitis

Injection Site Reactions

Minor reactions (normal): small area of redness, mild bruising, slight swelling at the injection site. Reassure the patient, document, and proceed normally at the next visit — use a different site.

Significant reactions (require action): expanding area of redness, warmth, induration (hardening), or purulent discharge suggests possible infection. Refer to the prescriber or urgent care. Document thoroughly including photo if patient consents.

Lipohypertrophy: if you notice a firm, raised nodule at a previous injection site, the patient has been injecting in the same spot too frequently. Revise the rotation protocol and avoid that site until it resolves (typically weeks to months).

Anaphylaxis (Rare but Possible)

Severe allergic reaction to a GLP-1 medication is rare but life-threatening. Any patient presenting with urticaria (hives), angioedema (swelling of lips, tongue, or throat), difficulty breathing, or hypotension following injection should be treated as anaphylaxis:

1. Call 911 immediately
2. Administer epinephrine 0.3mg IM (your clinic must stock an epinephrine auto-injector per your emergency protocol)
3. Position patient supine with legs elevated if hypotensive; upright if respiratory symptoms predominate
4. Follow your anaphylaxis SOP for further management until EMS arrives

Documentation Requirements for Every GLP-1 Injection Visit

Your chart entry for each GLP-1 injection visit must include, at minimum:

Pre-Injection

• Date, time, and administering provider
• Patient weight and BMI (calculated)
• Blood pressure and heart rate
• Symptom review findings — document "patient denies nausea, vomiting, abdominal pain, [etc.]" or detail any symptoms reported
• Current medication review — any changes since last visit?
• Confirmation that the prescription is valid and current

Injection Record

• Drug name and formulation (brand + generic)
• Dose administered (in mg)
• Lot number and expiration date of the medication vial or pen used
• Injection site (e.g., "right abdomen, lateral quadrant")
• Any deviation from standard technique and reason

Post-Injection

• Duration of post-injection observation (minimum 15 min for first-dose patients)
• Patient tolerance — "tolerated injection without adverse event" or document any reaction
• Next injection date and dose
• Any instructions given to the patient

Staff Training and Competency Requirements

Any clinical staff member administering GLP-1 injections must demonstrate competency before doing so independently. Your protocol should require:

• Initial training: review of the complete GLP-1 SOP, medication pharmacology, injection technique, and adverse event response. Document training date and trainer signature.
• Supervised practice: minimum 3 observed injections with a competency sign-off from the medical director or a designated clinical supervisor before independent administration
• Annual competency review: re-review of the SOP and updated protocols, documentation of completion
• Scope of practice verification: confirm that the staff member's license permits medication administration in your state (typically RN, LPN under RN supervision, NP, PA, or MA under physician supervision depending on state)